1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
669B8C469C76B7BAB65257EF4004058B9
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/69B8C469C76B7BAB65257EF4004058B9!OpenDocument
18
19OpenDocument
2035.172.224.102
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Market Research, Analytics and Forecasting Process Excellence and Productivity Management

Document Excerpt: Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Managing Honoraria & Non-Conforming Requests

DB Image

ID: MD-486


Features:

17 Info Graphics

14 Data Graphics

140 Metrics

8 Narratives


Pages/Slides: 4


Published: Pre-2017


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".


To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5385 " Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Managing Honoraria & Non-conforming Requests."


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Technology; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; actavis; Amgen; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; CSL Behring; Fresenius Kabi; Genentech; Grifols; Jazz Pharmaceuticals; Lilly; NeedleTech Products Inc.; Novartis; Novo Nordisk; Philips Healthcare; Roche; Sanofi; Teva Pharmaceutical Industries Ltd; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.